Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Jul 8, 2022
- Accession no.
- 0001562180-22-005637
- Filed
- Jul 8, 2022
- Trade date
- Jul 6-7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $318.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 | Common Stock | MOption exerciseAcquired | +15,009 | $6.38 | +$95,757.42 | 32,668 | Direct | |
| Jul 6, 2022 | Common Stock | SSaleDisposed | −15,009 | $21.07 | −$316,239.63 | 17,659 | Direct | |
| Jul 7, 2022 | Common Stock | MOption exerciseAcquired | +100 | $6.38 | +$638 | 17,759 | Direct | |
| Jul 7, 2022 | Common Stock | SSaleDisposed | −100 | $21.00 | −$2,100 | 17,659 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 | Common Stock | MOption exerciseDisposed | −15,009 | $0.00 | $0 | 0 | Direct | |
| Jul 7, 2022 | Common Stock | MOption exerciseDisposed | −100 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.